EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Rossmax International Ltd (4121) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Rossmax International Ltd TWD 38.40, price TWD 12.80, upside +200.0%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · TW · ISIN TW0004121009

RI Thin data Sep 23, 2026

Rossmax International Ltd

4121 · TWO

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value 38.40 TWD · Strongly undervalued (+200%)
!Quality 57/100
!Weak Growth (revenue 5y +0.6 %/yr)
!Loss-making · -1.1% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (4/10)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
Watch Rossmax International Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

34.59 TWD 11.65 TWD Fair Value 38.40 TWD May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range 11.65 TWD – 34.59 TWD · fair‑value band 30.65 TWD – 51.25 TWD · the 12.80 TWD price screens below the 38.40 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Rossmax International in your weekly email

Every Wednesday you see whether Rossmax International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rossmax International Ltd. develops and supplies healthcare products and solutions.

Show more

Rossmax International Ltd. develops and supplies healthcare products and solutions. The company offers body fat monitors and scales that are used to measure body fat, body mass index, lean mass, muscle mass, and water ratio along with body weight; blood pressure monitors; sphygmomanometer, a device that measures blood pressure; stethoscope, an acoustic medical device for auscultation, or listening to the internal sounds of an animal or human body; handheld pulse oximeter monitors to measure the amount of oxygen carried in the body; non-contact telephoto thermometers used to measure human body temperature; and blood glucose monitoring system, a medical device for determining the approximate concentration of glucose in the blood. It also provides nebulizer, a drug delivery device used to administer medication in the form of a mist; suction unit, a machine used to remove mucus and other bodily fluids; aero spacer, a device used to increase the ease of administering aerosolized medication; peak flow meter, a device used to monitor a person's ability to breathe out air; heating pads used for therapy; and anti-decubitus mattresses. In addition, the company operates Rossmax healthstyle app, which allows customers to monitor blood pressure, blood glucose, SpO2, weight, and temperature through a single app. It provides healthcare products in the fields of cardiovascular, diabetes, respiratory, fever, and wound healing diseases, as well as thermometers, scales, and nebulizers for kidshealth. The company also exports its products. It operates in Taiwan, America, Europe, East Asia, South Asia, India, Middle East, Africa, and internationally. Rossmax International Ltd. was founded in 1988 and is based in Taipei, Taiwan.

Stock analysis

Rossmax International Ltd (4121) currently trades at 12.80 TWD, while our model-based Fair Value estimate is 38.40 TWD, implying the stock looks roughly 66.7% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 44.51 TWD per share, and 10 of the 11 models we run sit above the 12.80 TWD price.

Bear case: the Asset-Based group reads lowest at 11.37 TWD, and 1 of the 11 models stay below the price. Evidence for this calculation is low.

Scenario range: 30.65 TWD (bear) to 51.25 TWD (bull), the price of 12.80 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Rossmax International Ltd reported revenue of 3.8B TWD in FY2025 versus 3.9B TWD in FY2021, a compound −1.0%/yr. Reported net income was −29.9M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $33.3M) · P/S ratio 0.29 · EPS (TTM) −0.4900 TWD · Dividend yield 4.4% · Net margin −0.8% · Return on equity −4.1% · Return on assets (EBIT) 1.9% · Operating margin −2.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 37% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 200%, 4121 screens cheaper than that median.

Fair Value models

Bear 30.65 TWD Fair Value 38.40 TWD Bull 51.25 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 34.85 TWD 44.51 TWD 63.44 TWD 81
Growth DCF 35.94 TWD 45.34 TWD 62.17 TWD 79
Owner Earnings 38.10 TWD 48.82 TWD 69.82 TWD 77
All 11 models by family
DCF Models
FCF DCF 34.85 TWD 44.51 TWD 63.44 TWD 81
Owner Earnings 38.10 TWD 48.82 TWD 69.82 TWD 77
5Y Revenue Exit 31.34 TWD 42.15 TWD 58.46 TWD 73
5Y EBITDA Exit 34.66 TWD 47.80 TWD 65.83 TWD 76
10Y Revenue Exit 31.83 TWD 41.19 TWD 51.66 TWD 68
10Y EBITDA Exit 34.49 TWD 44.81 TWD 56.28 TWD 70
Multiples
EV/EBITDA 39.25 TWD 50.62 TWD 62.00 TWD 67
EV/Revenue 31.06 TWD 42.17 TWD 53.28 TWD 54
Asset-Based
NCAV (Graham) 8.48 TWD 11.37 TWD 16.97 TWD 54
Growth DCF
Growth DCF 35.94 TWD 45.34 TWD 62.17 TWD 79
Rev-Margin DCF 31.34 TWD 42.85 TWD 57.54 TWD 73

Open the full fair value analysis →

Notify me when 4121 reaches fair value

Put 4121 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 56 · Market factors (momentum, volatility) 39

Profitability 31
Margins and returns on capital today
Quality Growth 31
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 86
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 97
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.5% (2020) → −1.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−28.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −29.1% a year for the price.

Watch 4121, get fair value alerts →

Compare Rossmax International Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside +200% · Top 25%
Profitability
Return on assets −2% · Below median
Net margin (TTM) −1% · Below median
Operating margin (TTM) −3% · Below median
Growth and dividend
Revenue growth −4% · Below median
Dividend yield (TTM) 4.4% · Top 25%
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/FCF 0.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)89 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $89.30 $65.57 −27%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rossmax International Ltd · Fair Value
38.40 TWD +67%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Rossmax International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4121

Frequently asked questions

Is Rossmax International Ltd (4121) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 38.40 TWD versus a price of 12.80 TWD, about +200% upside (undervalued).
What is the fair value of 4121?
Our model-based fair value for Rossmax International Ltd is 38.40 TWD (as of Sep 23, 2026), built from audited fundamentals. The current price: 12.80 TWD.
What is the quality score of 4121?
Rossmax International Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rossmax International Ltd (4121)?
Our model-based price target is the fair value of 38.40 TWD (as of Sep 23, 2026) from 11 valuation models. Cautious scenario 30.65 TWD, optimistic scenario 51.25 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Rossmax International Ltd stock forecast for 2026?
Our models put fair value at 38.40 TWD, about +200% upside versus a price of 12.80 TWD (undervalued). Cautious scenario 30.65 TWD, optimistic scenario 51.25 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Rossmax International Ltd (4121)?
Rossmax International Ltd reported trailing-twelve-month revenue of about 3.8B TWD (latest available figure, as of Sep 23, 2026).
Does Rossmax International Ltd pay a dividend?
Rossmax International Ltd currently shows a dividend yield of about 4.45% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Rossmax International Ltd (4121)?
For today's price to be fair in a discounted-cash-flow model, Rossmax International Ltd would have to grow free cash flow by -28.0 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 4121 use?
Our models discount Rossmax International Ltd at 9.0 %: a base by market capitalisation (nano), damped by beta 0.40, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Rossmax International Ltd that is -28.0 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Rossmax International Ltd (4121) delivered so far?
Over the past 5 years revenue at Rossmax International Ltd grew +0.7 % a year. The price currently implies -28.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Rossmax International Ltd (4121) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Rossmax International Ltd (-28.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Rossmax International Ltd (4121)?
The free-cash-flow yield on the price is 22.35 %: that much free cash flow Rossmax International Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Rossmax International Ltd (4121)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rossmax International Ltd it is 38.40 TWD per share (as of Sep 23, 2026), against a price of 12.80 TWD. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Rossmax International Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 4121 trades below its calculated fair value: price 12.80 TWD, fair value 38.40 TWD, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4121?
No. The price is what the market pays today (12.80 TWD); the fair value is what the company's own numbers justify (38.40 TWD). For Rossmax International Ltd the two are 25.60 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Rossmax International Ltd worth?
The market values Rossmax International Ltd at about 1.1B TWD (market capitalisation, as of Sep 23, 2026). Per share that is 12.80 TWD; our models calculate a fair value of 38.40 TWD per share.
What do the bullish and bearish scenarios say about 4121?
Our models span a range for Rossmax International Ltd: cautious scenario 30.65 TWD, base 38.40 TWD, optimistic 51.25 TWD per share (as of Sep 23, 2026, price 12.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rossmax International Ltd (4121)?
Balance-sheet figures for Rossmax International Ltd (as of Sep 23, 2026): return on equity −4.1%, debt of 0.13 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 4121 from its 52-week high?
Rossmax International Ltd trades at 12.80 TWD, about 37% below its 52-week high of 20.40 TWD and 2% above the low of 12.55 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 38.40 TWD is for.
Which stocks are comparable to Rossmax International Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rossmax International Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price 12.80 TWD, calculated fair value 38.40 TWD (+200%), Quality Score 57/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4121 calculated?
We run Rossmax International Ltd through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 38.40 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Rossmax International Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rossmax International Ltd (4121)?
The closing price on Sep 24, 2026 was 12.80 TWD. Our model-based fair value is 38.40 TWD, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rossmax International Ltd right now?
The price is below even our cautious bear case (30.65 TWD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Rossmax International Ltd

How large is the market capitalisation of Rossmax International Ltd (4121)?
The market capitalisation of Rossmax International Ltd is 1.1B TWD (≈ $33.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rossmax International Ltd (4121)?
The price-to-sales ratio of Rossmax International Ltd is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rossmax International Ltd (4121)?
Earnings per share at Rossmax International Ltd are −0.4900 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Rossmax International Ltd (4121)?
The dividend yield of Rossmax International Ltd is 4.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Rossmax International Ltd (4121)?
The net margin of Rossmax International Ltd is −0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rossmax International Ltd (4121)?
The return on equity (ROE) of Rossmax International Ltd is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rossmax International Ltd (4121)?
On an EBIT basis the return on assets of Rossmax International Ltd is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rossmax International Ltd (4121)?
The operating margin of Rossmax International Ltd is −2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rossmax International Ltd (4121)?
Revenue at Rossmax International Ltd is growing −3.6% versus a year earlier (3y avg −4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rossmax International Ltd (4121)?
Earnings per share at Rossmax International Ltd are growing −63.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Rossmax International Ltd (4121) carry?
The net debt of Rossmax International Ltd is 905M TWD (fiscal year 2023, ≈ 3.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rossmax International Ltd in the live analysis

One click puts Rossmax International Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.